Global Lung Cancer Therapeutics Market 2015-2019

肺がん治療薬の世界市場:非小細胞肺がん、小細胞肺がん

◆タイトル:Global Lung Cancer Therapeutics Market 2015-2019
◆商品コード:IRTNTR4668
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年11月26日
◆ページ数:126
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Five UserUSD3,300 ⇒換算¥356,400見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、肺がん治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、肺がん治療薬の世界市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Lung Cancer
Cancer occurs when, after undergoing cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Non-small cell lung cancer is the commonest type of lung cancer and forms almost 85-90 percent of the total cases diagnosed. It grows and spreads slowly. Smoking is considered as a major cause of lung cancer, though lung cancer also occurs in non-smokers. Non-small cell lung cancer is of three types: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Small cell lung cancers form roughly 10-15 percent of all the diagnosed cases of lung cancer. There are two types of small cell lung cancer: small cell carcinoma and combined small cell carcinoma. It can be classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer cannot be cured using current therapies available in the market. Some of the common symptoms associated with lung cancer are chest pain, persistent cough, blood in sputum, fatigue, loss of appetite, weight loss, shortness of breath, and wheezing. Both small cell lung cancer and non-small cell lung cancer are recurrent in nature, which are difficult to cure.

TechNavio’s analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 3.83 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Lung Cancer Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of non-small cell lung cancer and small cell lung cancer.
The Global Lung Cancer Therapeutics market is segmented based on the type of molecule used for the treatment of lung cancer, which include:
• Biologics
• Small molecules
In addition, the market is also segmented based on the route of administration followed for the treatment of lung cancer, which include:
• Oral
• Parenteral
TechNavio’s report, Global Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• AstraZeneca
• Celgene
• Eli Lilly
• F. Hoffmann-La Roche
• Pfizer

[Other Prominent Vendors]
• Abbvie
• Aetna
• Agennix
• Amgen
• Boehringer Ingelheim
• Celldex
• Eisai
• GlaxoSmithKline
• GTx
• Helsinn
• IMClone
• Merck Serono
• Novartis
• Qiagen
• OncoGenex
• OSI Pharmaceuticals
• Peregrine
• Pierre Fabre
• Sanofi
• Synta
• Telik
• Teva Pharmaceutical

[Market Driver]
• High Unmet Need
• For a full, detailed list, view our report

[Market Challenge]
• High Cost of Therapy
• For a full, detailed list, view our report

[Market Trend]
• Personalized Medicine
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Iressa
04.1.2 Abraxane
04.1.3 Alimta
04.1.4 Gemzar
04.1.5 Xalkori
04.1.6 Avastin
04.1.7 Tarceva

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Disease Overview
07.1 Understanding the Disease
07.2 Economic Burden
07.3 Classification of Lung Cancer
07.4 Diagnosis
07.5 Small Cell Lung Cancer
07.5.1 Rate of Incidence and Prevalence
07.5.2 Staging
07.5.3 Management
07.6 Non-small Cell Lung Cancer
07.6.1 Rate of Incidence and Prevalence
07.6.2 Staging

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Market Segmentation by Disease Type
09.1 Global Non-small Cell Lung Cancer Therapeutics Market
09.1.1 Market Size and Forecast
09.1.2 Market Segmentation by Molecule Type
09.1.3 Market Segmentation by Routes of Administration
09.2 Global Small Cell Lung Cancer Therapeutics Market
09.2.1 Market Size and Forecast

10.Market Segmentation by Molecule Type
10.1 Biologics
10.2 Small Molecules

11.Market Segmentation by Route of Administration
11.1 Oral
11.2 Parenteral

12.Geographical Segmentation
12.1 Global Non-Small-Cell Lung Cancer Market
12.2 Global Small Cell Lung Cancer Market

13.Buying Criteria

14.Market Growth Drivers

15.Drivers and their Impact

16.Market Challenges

17.Impact of Drivers and Challenges

18.Market Trends

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 AstraZeneca
20.2.2 Celgene
20.2.3 Eli Lilly
20.2.4 F. Hoffmann-La Roche
20.2.5 Pfizer
20.3 Other and Future Prominent Vendors

21.Pipeline Portfolio
21.1.1 Non-small Cell Lung Cancer
21.1.2 Small Cell Lung Cancer

22.Key Vendor Analysis
22.1 AstraZeneca
22.1.1 Key Facts
22.1.2 Business Description
22.1.3 Business Segmentation
22.1.4 Business Strategy
22.1.5 Revenue by Business Segmentation
22.1.6 Revenue Comparison 2011-2013
22.1.7 Sales Revenue by Geographical Segmentation
22.1.8 Key Developments
22.1.9 SWOT Analysis
22.2 Celgene
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Strategy
22.2.4 Business Segmentation by Revenue
22.2.5 Sales by Geography
22.2.6 Key Information
22.2.7 SWOT Analysis
22.3 Eli Lilly
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation by Revenue
22.3.4 Sales by Geography
22.3.5 Business Strategy
22.3.6 Key Information
22.3.7 SWOT Analysis
22.4 F. Hoffmann-La Roche Ltd.
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Sales by Geography
22.4.6 Business Strategy
22.4.7 Key Information
22.4.8 SWOT Analysis
22.5 Pfizer
22.5.1 Key Facts
22.5.2 Business Overview
22.5.3 Business Segmentation by Revenue 2013
22.5.4 Business Segmentation by Revenue 2012 and 2013
22.5.5 Geographical Segmentation by Revenue
22.5.6 Business Strategy
22.5.7 Key Developments
22.5.8 SWOT Analysis

23.Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Incidence Data of Lung Cancer pertaining to WHO Regions
Exhibit 3: Classification of Lung Cancer Types
Exhibit 4: Diagnosis of Lung Cancer in Patients
Exhibit 5: Staging of Small Cell Lung Cancer
Exhibit 6: Stepwise Diagrammatic Representation of the Management of Small Cell Lung Cancer According to the ESMO Guidelines
Exhibit 7: Types of Non-small Cell Lung Cancer
Exhibit 8: Percentage of Gene Mutations in Non-small Cell Lung Cancer
Exhibit 9: Staging of Non-small Cell Lung Cancer
Exhibit 10: Global Lung Cancer Therapeutics Market 2014-2019 (US$ million)
Exhibit 11: Global Lung Cancer Therapeutics Market Segmentation by Disease Type
Exhibit 12: Global Lung Cancer Therapeutics Market Segmentation by Disease Type 2014
Exhibit 13: YoY Revenue Comparison of Global Non-small Cell Lung Cancer Therapeutics market and Global Small Cell Lung Cancer Therapeutics market 2014-2019 (US$ million)
Exhibit 14: Global Non-small Cell Lung Cancer Therapeutics Market 2014-2019 (US$ million)
Exhibit 15: Global Non-Small-Cell Lung Cancer Market Segmentation by Molecule Type
Exhibit 16: Global Non-Small-Cell Lung Cancer Market Segmentation by Molecule Type 2014
Exhibit 17: Global Non-Small-Cell Lung Cancer Market Segmentation by Route of Administration
Exhibit 18: Global Non-Small-Cell Lung Cancer Market Segmentation by Routes of Administration 2014
Exhibit 19: Global Small Cell Lung Cancer Therapeutics Market 2014-2019 (US$ million)
Exhibit 20: Global Lung Cancer Therapeutics Market Segmentation by Molecule Type
Exhibit 21: Global Lung Cancer Therapeutics Market Segmentation by Molecule Type 2014
Exhibit 22: Global Lung Cancer Therapeutics Market Segmentation by Route of Administration
Exhibit 23: Global Lung Cancer Therapeutics Market Segmentation by Route of Administration 2014
Exhibit 24: Global Lung Cancer Therapeutics Market by Geographical Segmentation 2014
Exhibit 25: Global Non-small Cell Lung Cancer Market by Geographical Segmentation 2014
Exhibit 26: Global Small Cell Lung Cancer Market by Geographical Segmentation 2014
Exhibit 27: Buying Criteria of Global Lung Cancer Therapeutics Market 2014
Exhibit 28: Drivers of the Global Lung Cancer Therapeutics Market
Exhibit 29: Challenges of the Global Lung Cancer Therapeutics Market
Exhibit 30: Trends of the Global Lung Cancer Therapeutics Market
Exhibit 31: Global Lung Cancer Therapeutics Market by Vendor Segmentation 2014
Exhibit 32: Global Non-Small-Cell Lung Cancer Market by Market Share Analysis 2014
Exhibit 33: Sales Comparison of Major Drugs 2010-2013 (US$ million)
Exhibit 34: Sales of Iressa 2006-2013 (US$ million)
Exhibit 35: Sales of Iressa in Western Europe 2009-2013 (US$ million)
Exhibit 36: Sales of Iressa in Established ROW 2009-2013 (US$ million)
Exhibit 37: Sales of Iressa in Emerging Markets 2009-2013 (US$ million)
Exhibit 38: Region-wise Sales of Iressa 2009-2011 (US$ million)
Exhibit 39: Sales of Abraxane 2010-2013 (US$ million)
Exhibit 40: Sales of Alimta in US 2004-2013 (US$ million)
Exhibit 41: Sales of Alimta Outside US 2004-2013 (US$ million)
Exhibit 42: Total Sales of Alimta 2004-2013 (US$ million)
Exhibit 43: Region-wise Sales of Alimta 2004-2013 (US$ million)
Exhibit 44: Sales of Gemzar in US 2003-2011 (US$ million)
Exhibit 45: Sales of Gemzar Outside US 2003-2011 (US$ million)
Exhibit 46: Total Sales of Gemzar 2003-2011 (US$ million)
Exhibit 47: Region-wise Sales Gemzar 2003-2011 (US$ million)
Exhibit 48: Sales of Avastin and Tarceva 2005-2013 (US$ million)
Exhibit 49: Sales of Avastin 2005-2013 (US$ million)
Exhibit 50: Sales of Tarceva 2005-2013 (US$ million)
Exhibit 51: Sales Forecast for Xalkori 2013-2018 (US$ million)
Exhibit 52: Phase III Pipeline Portfolio of Global Lung Cancer Therapeutics Market by Disease Type 2014
Exhibit 53: Late-stage Pipeline Molecules for Non-small Cell Lung Cancer
Exhibit 54: Late-stage Pipeline Molecules for Small Cell Lung Cancer
Exhibit 55: Study Count of Small Cell Lung Cancer Clinical Trials by Geography
Exhibit 56: Study Count of Non-small Cell Lung Cancer Clinical Trials by Geography
Exhibit 57: AstraZeneca: Business Segmentation
Exhibit 58: AstraZeneca: Revenue by Business Segmentation 2013
Exhibit 59: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 60: AstraZeneca: Sales Revenue by Geographical Segmentation 2013
Exhibit 61: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 62: Celgene: Sales by Geography 2013
Exhibit 63: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 64: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 65: Eli Lilly: Sales by Geography 2013
Exhibit 66: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 67: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 68: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 69: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 70: Pfizer: Business Segmentation by Revenue 2013
Exhibit 71: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 72: Pfizer: Geographical Segmentation by Revenue 2013



【掲載企業】

AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche, Pfizer , Abbvie, Aetna, Agennix , Amgen, Boehringer Ingelheim, Celldex, Eisai, GlaxoSmithKline, GTx, Helsinn, IMClone, Merck Serono, Novartis, Qiagen, OncoGenex, OSI Pharmaceuticals, Peregrine,Pierre Fabre, Sanofi, Synta, Telik, Teva Pharmaceutical

【資料のキーワード】

肺がん治療薬、非小細胞肺がん、小細胞肺がん、製薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[肺がん治療薬の世界市場:非小細胞肺がん、小細胞肺がん] (Global Lung Cancer Therapeutics Market 2015-2019 / IRTNTR4668)販売に関する免責事項
[肺がん治療薬の世界市場:非小細胞肺がん、小細胞肺がん] (Global Lung Cancer Therapeutics Market 2015-2019 / IRTNTR4668)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆